Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

MDR-TB Patient shows daily drug dosis Photograph by Bithin Das
Press release
Press release |
06 March 2018
Research and development

MSF welcomes Members of the European Parliament response to the US pharmaceutical pressure to stop EU action on high drug prices

Vials of PCV13, a vaccine that protects children against pneumonia and meningitis. At 9 Euros a dose (three doses are necessary for the vaccine to be effective) PCV13 is currently priced at a rate much higher than most people in Central African Republic can afford. Photograph by Sandra Smiley Photograph by Sandra Smiley
Press release
Press release |
06 February 2018
Intellectual property and trade Vaccines
Republic of Korea

MSF challenges Pfizer’s monopoly on lifesaving pneumonia vaccine in Korea

4 min
Photograph by Siddharth Singh Photograph by Siddharth Singh

IP RCEP protest in India.

Press release
Press release |
18 December 2017
Hepatitis C
China

MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices

MSF172231 Photograph by Alexis Huguet/Hans Lucas
Press release
Press release |
04 December 2017
HIV/AIDS

Delivering differently to reach people living with HIV in West and Central Africa

6 min
Mark Walsh, head of mission for MSF in Ukraine officially opening MSF’s project with Ivan Dudla, medical specialist from the regional health authorities in Mykolaiv. Photograph by MSF
Press release
Press release |
01 December 2017
Hepatitis C
Ukraine

Ukraine: People co-infected with HIV to receive hepatitis C treatment in Mykolaiv region

5 min
Immunization campaign at Endebess Hospital organized by MSF with the Ministry of Health. Photograph by Brendan Bannon Photograph by Brendan Bannon
Press release
Press release |
28 November 2017
Vaccines

20 countries about to fall off Gavi funding ‘cliff,’ risking their ability to pay for life-saving vaccines for children long term

2013 marked the first time that PCV is being used in South Sudan and one of the first vaccines to be implemented in compliance with the new WHO emergency vaccination recommendations. Photograph by Yann Libessart
Press release
Press release |
20 November 2017
Vaccines
India

MSF: India’s decision to give Pfizer unmerited patent on lifesaving pneumonia vaccine limits access for children globally

3 min
Photograph by Atul Loke Photograph by Atul Loke
Press release
Press release |
17 November 2017
Tuberculosis

MSF response to “Moscow Declaration to End TB”

  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury